Shares of Strongbridge Biopharma SBBP moved higher by 0.6% in pre-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share increased 56.00% over the past year to ($0.11), which beat the estimate of ($0.12).
Revenue of $8,226,000 rose by 46.74% from the same period last year, which beat the estimate of $8,040,000.
Looking Ahead
The upcoming fiscal year's revenue expected to be between $34,000,000 and $36,000,000.
Details Of The Call
Date: Mar 03, 2021
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/zbsmiua5
Technicals
52-week high: $4.63
52-week low: $1.50
Price action over last quarter: Up 61.03%
Company Profile
Strongbridge Biopharma PLC is a biopharmaceutical company which focuses on the development, in-licensing, acquisition, and commercialization of various complementary products and product candidates that target rare diseases. The product portfolio of the group includes COR-003(levoketoconazole) and COR-005 (veldoreotide). COR-003 is a cortisol inhibitor which is used for the treatment of endogenous cushing's syndrome and COR-005 a novel somatostatin analog, which is used for the treatment of acromegaly. In addition, it is also developing BP-2002 (gene modified probiotic) which will be used for the treatment of Diabetes. Geographically, business activity of the firm is primarily functioned through the United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.